SEPR drop yesterday; policy issues
Good morning gents, if you don't mind my intrusion (after a horrible spate at the office that has kept me--to some perhaps mercifully so--off all threads):
My take was that the drop was normal, and even to be expected, in light of a weak market, a relatively quick run-up from the 60 range (traders and profit-takers), then the pause, drop and run-up again, combined with a stock that still has not quite regained its footing after a dreadful Spring (viz. all this Kensey or whatever touting SEPR on his short list). I don't know if the SGP announcement was the type of news that Lind had in mind when he referred to second half news that would get the stock in gear again. I suspect that news will have to be in the nature of any of blockbuster trial results, new partnership (maybe Nori) or acceleration of filing dates in order for the stock to get out of the 70's and low 80's, meaning northbound.
One of my fears expressed on this thread from time to time has been looming political developments and figures casting shadows over the pharma and near pharma segment. Has any one any thoughts on the apparently imminent debate on Medicare coverage? Is the potential for cost containment on prescription drug prices (at least within the Medicare patient universe) offset to any meaningful degree by wider usage arising out of Medicare coverage? Is it appropriate to assume that regulation of any kind, even within the putative umbrella of wider availability because of program coverage, is a negative for us? An additional query: is SEPR's product pipeline, on balance, one that lends itself heavily to treatment of the aged (to which state of grace we have all advanced more rapidly this Spring)? My own sense is that it is not.
Regards. Steven |
